חוב כולל של החברה: VolitionRx Ltd. (VNRX)

The total debt load reflects the liability dynamics of VolitionRx Limited (VNRX), where the 0.00 metric serves as the target level. The increase in debt is linked to the development of Nu.Q within the veterinary sector and the anticipation of FDA approvals. Meanwhile, VolitionRx Limited (VNRX) partially delegates component production and distribution to external partners, focusing on the creation of affordable early-detection oncology systems via blood analysis.

This indicator aggregates the total borrowed obligations of the issuer, allowing for an assessment of default risk and the extent of capital dependence on external financing. By analyzing the credit portfolio dynamics of VolitionRx Limited (VNRX), an investor can determine the degree to which the scaling of the digital distribution platform for cancer tests relies on borrowed funds, confirming the financial stability of VolitionRx Limited (VNRX) amid the expansion of medical sales.